Literature DB >> 24227980

Proton beam radiotherapy of uveal melanoma.

Bertil Damato1, Andrzej Kacperek, Doug Errington, Heinrich Heimann.   

Abstract

Proton beam radiotherapy of uveal melanoma can be administered as primary treatment, as salvage therapy for recurrent tumor, and as neoadjuvant therapy prior to surgical resection. The physical properties of proton beams make it possible to deliver high-doses of radiation to the tumor with relative sparing of adjacent tissues. This form of therapy is effective for a wider range of uveal melanoma than any other modality, providing exceptionally-high rates of local tumor control. This is particularly the case with diffuse iris melanomas, many of which are unresectable. The chances of survival, ocular conservation, visual preservation and avoidance of iatrogenic morbidity depend greatly on the tumor size, location and extent. When treating any side-effects and/or complications, it is helpful to consider whether these are the result of collateral damage or persistence of the irradiated tumor ('toxic tumor syndrome').

Entities:  

Keywords:  Mortality; Neoadjuvant therapy; Proton beam radiotherapy; Recurrent tumor; Uveal melanoma

Year:  2013        PMID: 24227980      PMCID: PMC3770228          DOI: 10.1016/j.sjopt.2013.06.014

Source DB:  PubMed          Journal:  Saudi J Ophthalmol        ISSN: 1319-4534


  22 in total

1.  Proton beam radiotherapy of iris melanoma.

Authors:  Bertil Damato; Andrzej Kacperek; Mona Chopra; Martin A Sheen; Ian R Campbell; R Douglas Errington
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

2.  Neoadjuvant proton beam radiotherapy combined with subsequent endoresection of choroidal melanomas.

Authors:  Nikolaos E Bechrakis; Michael H Foerster
Journal:  Int Ophthalmol Clin       Date:  2006

3.  Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma.

Authors:  I K Daftari; D H Char; L J Verhey; J R Castro; P L Petti; W J Meecham; S Kroll; E A Blakely
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-12-01       Impact factor: 7.038

4.  Iris melanoma: features and prognosis in 317 children and adults.

Authors:  Carol L Shields; Swathi Kaliki; Sanket U Shah; Wenjuan Luo; Minoru Furuta; Jerry A Shields
Journal:  J AAPOS       Date:  2012-02       Impact factor: 1.220

5.  Endoresection of choroidal melanoma.

Authors:  B Damato; C Groenewald; J McGalliard; D Wong
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

Review 6.  Treatment of uveal melanoma by accelerated proton beam.

Authors:  Laurence Desjardins; Livia Lumbroso-Le Rouic; Christine Levy-Gabriel; Nathalie Cassoux; Remi Dendale; Alexandro Mazal; Sabine Delacroix; Xavier Sastre; Corine Plancher; Bernard Asselain
Journal:  Dev Ophthalmol       Date:  2011-10-21

7.  Survival implications of enucleation after definitive radiotherapy for choroidal melanoma: an example of regression on time-dependent covariates.

Authors:  K M Egan; L M Ryan; E S Gragoudas
Journal:  Arch Ophthalmol       Date:  1998-03

Review 8.  Eye retention after proton beam radiotherapy for uveal melanoma.

Authors:  Emmanuel Egger; Leonidas Zografos; Ann Schalenbourg; Donata Beati; Terence Böhringer; Line Chamot; Gudrun Goitein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-03-15       Impact factor: 7.038

9.  Baerveldt implant for secondary glaucoma due to iris melanoma.

Authors:  Annelie N Tan; Juliette G M M Hoevenaars; Carroll A B Webers; Bertil Damato; Henny J M Beckers
Journal:  Clin Ophthalmol       Date:  2010-05-06

10.  Photodynamic therapy for recurrent hyphema after proton beam radiotherapy of iris melanoma.

Authors:  Nikolaos Trichopoulos; Bertil Damato
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-12       Impact factor: 3.117

View more
  15 in total

Review 1.  [CyberKnife®: new treatment option for uveal melanoma].

Authors:  J M Mor; R Semrau; W Baus; K R Koch; F Schaub; C Cursiefen; S Marnitz; L M Heindl
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

2.  Outcomes of Proton Beam Radiotherapy for Large Non-Peripapillary Choroidal and Ciliary Body Melanoma at TRIUMF and the BC Cancer Agency.

Authors:  Britta Weber; Katherine Paton; Roy Ma; Tom Pickles
Journal:  Ocul Oncol Pathol       Date:  2015-07-09

3.  Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results.

Authors:  Pietro Valerio Foti; Renato Farina; Maria Coronella; Stefano Palmucci; Angelo Montana; Alessandra Sigona; Michele Reibaldi; Antonio Longo; Andrea Russo; Teresio Avitabile; Rosario Caltabiano; Lidia Puzzo; Marco Ragusa; Cesare Mariotti; Pietro Milone; Giovanni Carlo Ettorre
Journal:  Radiol Med       Date:  2015-01-13       Impact factor: 3.469

4.  Ruthenium-106 plaque radiotherapy for uveal melanoma: analysis of tumor dimension and location on anatomical and functional results.

Authors:  Reza Mirshahi; Ahad Sedaghat; Ramin Jaberi; Zohreh Azma; Mehdi Mazloumi; Masood Naseripour
Journal:  BMC Ophthalmol       Date:  2022-07-16       Impact factor: 2.086

5.  Carbon Fiducial Markers for Tumor Localization in Stereotactic Irradiation of Uveal Melanoma.

Authors:  Timothy T Xu; Jose S Pulido; Ian F Parney; Cristiane M Ida; Lauren A Dalvin; Timothy W Olsen
Journal:  Ocul Oncol Pathol       Date:  2021-08-03

6.  Uveal melanoma: quantitative evaluation of diffusion-weighted MR imaging in the response assessment after proton-beam therapy, long-term follow-up.

Authors:  Pietro Valerio Foti; Antonio Longo; Michele Reibaldi; Andrea Russo; Giuseppe Privitera; Corrado Spatola; Luigi Raffaele; Vincenzo Salamone; Renato Farina; Stefano Palmucci; Andrea Musumeci; Rosario Caltabiano; Marco Ragusa; Cesare Mariotti; Teresio Avitabile; Pietro Milone; Giovanni Carlo Ettorre
Journal:  Radiol Med       Date:  2016-10-17       Impact factor: 3.469

Review 7.  [Uveal and iridociliary melanomas in young patients : A retrospective analysis of 57 cases].

Authors:  L J Heyer; C Metz; D Flühs; C M Heyer; N Bornfeld
Journal:  Ophthalmologe       Date:  2016-12       Impact factor: 1.059

Review 8.  Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: treatment indications and complications.

Authors:  Pietro Valerio Foti; Mario Travali; Renato Farina; Stefano Palmucci; Corrado Spatola; Rocco Luca Emanuele Liardo; Roberto Milazzotto; Luigi Raffaele; Vincenzo Salamone; Rosario Caltabiano; Giuseppe Broggi; Lidia Puzzo; Andrea Russo; Michele Reibaldi; Antonio Longo; Paolo Vigneri; Teresio Avitabile; Giovani Carlo Ettorre; Antonio Basile
Journal:  Insights Imaging       Date:  2021-06-04

Review 9.  Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part I: MR imaging with pathologic correlation and technical considerations.

Authors:  Pietro Valerio Foti; Mario Travali; Renato Farina; Stefano Palmucci; Corrado Spatola; Luigi Raffaele; Vincenzo Salamone; Rosario Caltabiano; Giuseppe Broggi; Lidia Puzzo; Andrea Russo; Michele Reibaldi; Antonio Longo; Paolo Vigneri; Teresio Avitabile; Giovani Carlo Ettorre; Antonio Basile
Journal:  Insights Imaging       Date:  2021-06-03

Review 10.  Uveal Melanoma: Current Trends in Diagnosis and Management.

Authors:  Berçin Tarlan; Hayyam Kıratlı
Journal:  Turk J Ophthalmol       Date:  2016-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.